No company is going to make a counter bid without being able to do their due diligence (as per terms of the scheme). Also not as many companies are able to extract as much value from the product as it currently stands as Pfizer will be able to.
If the tech wasn't special Pfizer would not want it. Pfizer don't want to acquire the company out of charity because they feel sorry for us investors, they want the company because the IP (specifically the covid cough detection, I'm still of the mindset that they don't really care about the other verticals the company has) will allow them to increase sales of their covid antiviral by a factor at least greater than the price they're willing the buy the company at (the reality would be multiples of that).
The only reason we're in this predicament is because the BOD went along with this whole thing. If they just raised funds off the back of the good news at the time (positive results of COVID test) we would be in a much better place. Of course it's obvious they're incentivised by more than the offer price to push the deal, otherwise they'd never have pushed for it back at the original offer price. Now they have an added problem of not only little left in the kitty, but the reality they might have to raise funds after essentially saying their's no future for the company.
There's no reason they couldn't negotiate terms for an exclusive license (beyond simply failing to repay a small loan LOL).
RAP Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
